WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective PPARα agonist with an IC50 of 10.11 µM for human PPARα, enabling robust modulation of lipid metabolism and inflammatory signaling in cellular and animal models (APExBIO). In rodent studies, oral or intraperitoneal administration of WY-14643 at 3–100 mg/kg/day significantly reduces plasma glucose, triglycerides, and hepatic steatosis, while enhancing insulin sensitivity without promoting weight gain (APExBIO). Mechanistically, WY-14643 activates PPARα-dependent transcription and, via α-substitution, can act as a dual PPARα/γ agonist in the low micromolar range. It also mediates moderate hepatic TNFα mRNA elevation and downregulates VCAM-1 in endothelial models, supporting anti-inflammatory applications. Its physicochemical properties (insoluble in water, soluble in DMSO and ethanol, stable at -20°C) make it suitable for diverse research workflows.

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that regulate genes involved in lipid metabolism, glucose homeostasis, and inflammatory signaling. Among the subtypes, PPARα is predominantly expressed in liver, heart, and skeletal muscle, orchestrating fatty acid β-oxidation and modulating the acute phase response. Dysregulation of PPARα activity is implicated in metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disorders (WY-14643: Dissecting PPARα Signaling). Activation of PPARα with selective agonists such as WY-14643 allows targeted investigation of these metabolic and inflammatory pathways, providing mechanistic clarity and translational potential. Compared to broader PPAR ligands, WY-14643's selectivity minimizes confounding off-target effects, facilitating precise dissection of PPARα-specific mechanisms.

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds PPARα in the ligand-binding domain, stabilizing the active conformation and promoting heterodimerization with retinoid X receptor (RXR). The PPARα–RXR complex then binds peroxisome proliferator response elements (PPREs) in target gene promoters, upregulating genes involved in fatty acid transport (e.g., CPT1, ACOX1), β-oxidation, and anti-inflammatory mediators. WY-14643's IC50 for human PPARα is 10.11 µM, demonstrating high potency (APExBIO). Aliphatic α-substitution of WY-14643 has been shown to enhance dual PPARα/γ agonism, expanding its utility in contexts requiring balanced modulation of both receptors (Advanced Insights into PPARα Modulation). At the cellular level, WY-14643 reduces endothelial VCAM-1 expression and monocyte adhesion in response to TNF-α, indicating direct anti-inflammatory action. In hepatic tissue, WY-14643 elevates TNFα mRNA via Kupffer cells, indirectly promoting hepatocyte mitogenesis and regeneration (see Evidence & Benchmarks).

Evidence & Benchmarks

• WY-14643 at 3 mg/kg/day orally for 2 weeks in high-fat diet rats lowers plasma glucose, triglycerides, and leptin, while reducing visceral and hepatic triglyceride content; insulin sensitivity is enhanced without significant weight gain (APExBIO).
• In C57BL/6 mice, 100 mg/kg/day intraperitoneal WY-14643 induces hepatomegaly and liver regeneration, dependent on PPARα and YAP-TEAD signaling; effects abrogated in PparaΔHep or YapΔHep mice (Wang et al., HEP-21-0169, Capital Medical University Supporting Material).
• Pretreatment of endothelial cells with 250 μM WY-14643 downregulates TNF-α-induced VCAM-1 expression and reduces monocyte adhesion, supporting anti-inflammatory effects (Selective PPARα Agonist for Metabolic and Inflammation Research).
• WY-14643 is insoluble in water but dissolves in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance) at room temperature; solutions are stable for short-term use if stored at -20°C (APExBIO).
• WY-14643 moderately elevates hepatic TNFα mRNA via Kupffer cells, indirectly promoting hepatocyte proliferation; this is associated with increased Ki67+ hepatocytes after partial hepatectomy (Wang et al., HEP-21-0169).

This article clarifies the mechanistic and translational scope of WY-14643 beyond reviews such as this analysis, by providing detailed benchmarks and integration guidance.

Applications, Limits & Misconceptions

WY-14643 is widely used in metabolic research, including studies on lipid homeostasis, insulin sensitivity, and TNF-α-mediated inflammation. It is also a tool for dissecting PPARα and dual PPARα/γ signaling in preclinical models of metabolic syndrome, NAFLD, and tumor microenvironment reprogramming (PPARα Agonist in Tumor Microenvironment). This article updates previous work by detailing the compound's physicochemical and workflow parameters, supporting reproducible results in both cell and animal systems. However, its selectivity is concentration-dependent, and higher doses may activate PPARγ or elicit off-target effects. WY-14643 is not suitable for use as a human therapeutic or diagnostic agent, and all studies must be conducted in compliance with institutional and safety guidelines.

Common Pitfalls or Misconceptions

• WY-14643 is not soluble in water; improper dissolution may result in inaccurate dosing or precipitation in biological solutions.
• High concentrations (>100 μM) may activate PPARγ or induce cytotoxicity in sensitive cell lines; always titrate for specific context.
• The compound is not approved for clinical or diagnostic use; all applications are for research purposes only.
• WY-14643-induced hepatomegaly is dependent on intact PPARα and YAP-TEAD signaling pathways; genetic knockouts may not recapitulate full pharmacological effects.
• Short-term stability of solutions requires strict storage at -20°C to prevent degradation or loss of activity.

Workflow Integration & Parameters

WY-14643 (A4305, APExBIO) should be dissolved in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonic assistance) for stock solutions. Working concentrations typically range from 1–250 μM for cellular assays and 3–100 mg/kg/day for in vivo rodent studies, depending on experimental goals (product details). Solutions should be prepared fresh or stored at -20°C for short-term use. For in vivo studies, administration can be oral or intraperitoneal, with endpoints including serum lipid panels, glucose tolerance, hepatic histology, and gene expression profiling.

Compared to prior articles such as this systems-biology perspective, this guide emphasizes practical details for compound handling, dosing, and analytical endpoints.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a benchmark PPARα agonist for metabolic disorder research, enabling precise modulation of lipid metabolism, insulin sensitivity, and inflammation. Its robust, reproducible effects in preclinical models make it indispensable for dissecting PPAR signaling pathways. Advances in dual PPARα/γ agonism and integration into tumor microenvironment studies expand its translational relevance, as detailed in recent analyses. For detailed product specifications and ordering, refer to the APExBIO WY-14643 page.